$8.89
0.79% today
Nasdaq, Sep 04, 10:00 pm CET
ISIN
US29251M1062
Symbol
ENTA

Enanta Pharmaceuticals, Inc. Stock price

$8.89
+1.79 25.21% 1M
+1.65 22.79% 6M
+3.14 54.61% YTD
-3.25 26.77% 1Y
-54.98 86.08% 3Y
-39.78 81.73% 5Y
-29.98 77.13% 10Y
-8.29 48.25% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
+0.07 0.79%
ISIN
US29251M1062
Symbol
ENTA
Industry

Key metrics

Basic
Market capitalization
$188.6m
Enterprise Value
$-14.2m
Net debt
positive
Cash
$204.1m
Shares outstanding
21.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.9 | 2.8
EV/Sales
negative | negative
EV/FCF
0.3
P/B
2.4
Financial Health
Equity Ratio
34.2%
Return on Equity
-90.1%
ROCE
-37.8%
ROIC
-144.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$64.8m | $67.2m
EBITDA
$-93.0m | $-92.8m
EBIT
$-96.8m | $-95.9m
Net Income
$-92.0m | $-93.0m
Free Cash Flow
$-43.6m
Growth (TTM | estimate)
Revenue
-9.9% | -0.6%
EBITDA
22.7% | 22.2%
EBIT
21.2% | 21.2%
Net Income
20.2% | 19.9%
Free Cash Flow
56.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-143.6% | -138.1%
EBIT
-149.4%
Net
-142.0% | -138.3%
Free Cash Flow
-67.2%
More
EPS
$-4.3
FCF per Share
$-2.0
Short interest
14.3%
Employees
131
Rev per Employee
$520.0k
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
65 65
10% 10%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 48 48
17% 17%
74%
- Research and Development Expense 114 114
17% 17%
175%
-93 -93
23% 23%
-144%
- Depreciation and Amortization 3.78 3.78
49% 49%
6%
EBIT (Operating Income) EBIT -97 -97
21% 21%
-149%
Net Profit -92 -92
20% 20%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
one day ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. “The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since joining the Compa...
Neutral
Business Wire
14 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesday, September 3, ...
Neutral
Business Wire
15 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seek...
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 131
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today